Ieq Capital LLC Makes New Investment in Stryker Corporation $SYK

Ieq Capital LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 28,828 shares of the medical technology company's stock, valued at approximately $9,076,000.

Several other institutional investors have also modified their holdings of SYK. Varma Mutual Pension Insurance Co lifted its holdings in shares of Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock valued at $18,842,000 after purchasing an additional 5,100 shares in the last quarter. QRG Capital Management Inc. grew its holdings in shares of Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock worth $21,281,000 after buying an additional 4,186 shares in the last quarter. Swedbank AB raised its position in Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock valued at $45,349,000 after buying an additional 7,934 shares during the last quarter. Royal Bank of Canada lifted its stake in Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock valued at $1,075,552,000 after acquiring an additional 199,863 shares in the last quarter. Finally, Crossmark Global Holdings Inc. boosted its position in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock worth $9,426,000 after acquiring an additional 6,367 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Up 0.1%

NYSE:SYK opened at $329.86 on Monday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The firm has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock's 50 day moving average price is $326.99 and its two-hundred day moving average price is $332.39.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 EPS. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 665,370 shares of company stock worth $216,238,501 in the last ninety days. Insiders own 4.60% of the company's stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SYK shares. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research note on Friday, May 1st. The Goldman Sachs Group reissued a "neutral" rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Canaccord Genuity Group reduced their target price on shares of Stryker from $435.00 to $400.00 and set a "buy" rating for the company in a report on Friday, May 1st. JPMorgan Chase & Co. decreased their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Finally, Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source